Clinical Trial News

The SPLASH Phase 3 trial showed significant improvement in radiographic progression-free survival with 177Lu-PNT2002 in mCRPC patients, with a 38.1% overall response rate vs. 12.0% for ARPI. Patients also demonstrated improved health-related quality of life and statistically significant overall survival benefits. The study met its primary endpoint, with a median rPFS of 9.5 months for 177Lu-PNT2002 vs. 6.0 months for ARPI.

About half of metastatic melanoma patients treated with immune checkpoint inhibitors survive cancer-free for 10+ years, according to a 10-year follow-up study from Dana-Farber Cancer Center and Weill Cornell Medicine. The CheckMate 067 trial, involving 945 patients, showed combining nivolumab and ipilimumab significantly improved outcomes. The study found no new safety concerns and suggests long-term treatment success.

CONTACT-02 trial showed Cabometyx® + atezolizumab had a positive trend in overall survival but lacked statistical significance. Ipsen will not pursue regulatory submissions for this combination outside the US and Japan. Confidence remains in Cabometyx's profile as a monotherapy and in combination with immunotherapy.

10-year follow-up data from KEYNOTE-006 trial shows 34.0% of advanced melanoma patients treated with KEYTRUDA were alive, compared to 23.6% with ipilimumab. KEYTRUDA demonstrated sustained OS benefits, reducing death risk by 29%.

Initial results from Daiichi Sankyo’s phase 1 trial of DS-9606, a CLDN6-directed ADC, show promising clinical activity in advanced solid tumors expressing CLDN6, with no dose-limiting toxicities observed.

TAR-200 monotherapy shows 83.5% complete response rate in BCG-unresponsive HR-NMIBC patients, with 82% maintaining response after 9.2 months, highlighting its potential as a bladder-sparing treatment alternative to radical cystectomy.

TAR-200 monotherapy shows 83.5% complete response rate in BCG-unresponsive HR-NMIBC patients, with 82% maintaining response after 9 months.

Lenvatinib, pembrolizumab, and TACE significantly improved progression-free survival (PFS) for intermediate-stage hepatocellular carcinoma (HCC) patients compared to placebo and TACE, according to the phase 3 LEAP-012 study. Median PFS was 14.6 months vs. 10.0 months, with a hazard ratio of 0.66 (P = .0002). The treatment regimen showed manageable safety and no new concerns, suggesting it could be a new option for this patient group.

IBI363 received FDA designation.

KHCC announces breakthrough in cancer treatment using lab-engineered T-lymphocytes (CAR-T) for blood cancer patients, supported by a state-of-the-art GMP facility. This pioneering immunotherapy increases chances of eradicating tumors and reduces relapse rates, positioning KHCC as a global leader in advanced cancer treatment.